WO2002090974A3 - Verfahren zum nachweis einer progedienten, chronisch-demenziellen erkrankung, zugehörige peptide und nachweisreagenzien - Google Patents

Verfahren zum nachweis einer progedienten, chronisch-demenziellen erkrankung, zugehörige peptide und nachweisreagenzien Download PDF

Info

Publication number
WO2002090974A3
WO2002090974A3 PCT/DE2002/001665 DE0201665W WO02090974A3 WO 2002090974 A3 WO2002090974 A3 WO 2002090974A3 DE 0201665 W DE0201665 W DE 0201665W WO 02090974 A3 WO02090974 A3 WO 02090974A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptides
chronic dementia
progredient
progredient chronic
dementia
Prior art date
Application number
PCT/DE2002/001665
Other languages
English (en)
French (fr)
Other versions
WO2002090974A2 (de
Inventor
Norbert Lamping
Hans-Dieter Zucht
Gabriele Heine
Michael Juergens
Ruediger Hess
Hartmut Selle
Original Assignee
Biovision Ag
Norbert Lamping
Hans-Dieter Zucht
Gabriele Heine
Michael Juergens
Ruediger Hess
Hartmut Selle
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovision Ag, Norbert Lamping, Hans-Dieter Zucht, Gabriele Heine, Michael Juergens, Ruediger Hess, Hartmut Selle filed Critical Biovision Ag
Priority to DE10291986T priority Critical patent/DE10291986D2/de
Priority to US10/476,976 priority patent/US7202044B2/en
Priority to EP02742729A priority patent/EP1389306A2/de
Priority to AU2002341488A priority patent/AU2002341488A1/en
Priority to CA002446666A priority patent/CA2446666A1/en
Priority to JP2002588182A priority patent/JP2004532633A/ja
Publication of WO2002090974A2 publication Critical patent/WO2002090974A2/de
Publication of WO2002090974A3 publication Critical patent/WO2002090974A3/de
Priority to US11/726,160 priority patent/US20070264197A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Die vorliegende Erfindung betrifft definierte Peptide und deren quantitative Bestimmung in Körperflüssigkeiten von Patienten, die an progredienten, chronisch-demenzeillen Erkrankungen leiden, relativ zu deren Konzentration in einer Kontrollgruppe. Die erfindungsgemässen Peptide entstammen aus einem Proteinvorläufer mit dem korrespondierenden Gen und sind in spezifischer Art und Weise prozessiert und ggf. posttranslational modifiziert, insbesondere phosphoryliert. Ein Anstieg der Konzentrationen dieser Peptide oder des zugehörigen nicht prozessierten Proteins zeigt eine progrediente, chronisch Demenzielle Erkrankung an. Der Nachweis der progredienten, chronisch-demenzeillen Erkrankung erfolgt durch eine Identifizierung der Peptide und/oder des Proteins einzeln oder in Kombinationen. Die Erfindung findet darüber hinaus Verwendung zur Verlaufskontrolle von progredienten, chronisch-demenzeillen Erkrankungen und zu ihrer Prognose, insbesondere zur Ergänzung oder als Ersatz des 'Mini-Mental Scores', sowie zur Entwicklung von Therapeutika gegen progrediente, chronisch-demenzeille Erkrankungen wie z.B. Morbus Alzheimer.
PCT/DE2002/001665 2001-05-09 2002-05-08 Verfahren zum nachweis einer progedienten, chronisch-demenziellen erkrankung, zugehörige peptide und nachweisreagenzien WO2002090974A2 (de)

Priority Applications (7)

Application Number Priority Date Filing Date Title
DE10291986T DE10291986D2 (de) 2001-05-09 2002-05-08 Verfahren zum Nachweis einer progredienten, chronisch-demenziellen Erkrankung, zugehörige Peptide und Nachweisreagenzien
US10/476,976 US7202044B2 (en) 2001-05-09 2002-05-08 Method for detecting a progressive, chronic dementia disease, and corresponding peptides and detection agents
EP02742729A EP1389306A2 (de) 2001-05-09 2002-05-08 Verfahren zum nachweis einer progedienten, chronisch-demenziellen erkrankung, zugehörige peptide und nachweisreagenzien
AU2002341488A AU2002341488A1 (en) 2001-05-09 2002-05-08 Method for detecting progredient chronic dementia, and associated peptides and detection reagents
CA002446666A CA2446666A1 (en) 2001-05-09 2002-05-08 Method for detecting progredient chronic dementia, and associated peptides and detection reagents
JP2002588182A JP2004532633A (ja) 2001-05-09 2002-05-08 進行性の慢性痴呆疾患の検出方法、これに適したペプチド及び検出試薬
US11/726,160 US20070264197A1 (en) 2001-05-09 2007-03-20 Method for detecting a progressive, chronic dementia disease, and corresponding peptides and detection reagents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10122543.1 2001-05-09
DE10122543 2001-05-09

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/726,160 Division US20070264197A1 (en) 2001-05-09 2007-03-20 Method for detecting a progressive, chronic dementia disease, and corresponding peptides and detection reagents

Publications (2)

Publication Number Publication Date
WO2002090974A2 WO2002090974A2 (de) 2002-11-14
WO2002090974A3 true WO2002090974A3 (de) 2003-05-08

Family

ID=7684167

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2002/001665 WO2002090974A2 (de) 2001-05-09 2002-05-08 Verfahren zum nachweis einer progedienten, chronisch-demenziellen erkrankung, zugehörige peptide und nachweisreagenzien

Country Status (7)

Country Link
US (2) US7202044B2 (de)
EP (1) EP1389306A2 (de)
JP (1) JP2004532633A (de)
AU (1) AU2002341488A1 (de)
CA (1) CA2446666A1 (de)
DE (1) DE10291986D2 (de)
WO (1) WO2002090974A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070031908A1 (en) * 2003-03-18 2007-02-08 Norbert Lamping Method for detecting a progressive, chronic dementia disease, and corresponding peptides and detection reagents
EP2369348A1 (de) * 2003-11-07 2011-09-28 Ciphergen Biosystems, Inc. Biomarker für Morbus Alzheimer
JP5496513B2 (ja) * 2006-02-28 2014-05-21 フェノメノーム ディスカバリーズ インク 認知症及び他の神経障害の診断方法
US9034923B2 (en) 2007-02-08 2015-05-19 Phenomenome Discoveries Inc. Methods for the treatment of senile dementia of the alzheimer's type
KR20200091961A (ko) 2008-01-18 2020-07-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 체액 내에서 질병 또는 병태의 시그너쳐의 검출 방법
EP2596353A4 (de) 2010-07-23 2014-01-15 Harvard College Verfahren zum nachweis pränataler oder schwangerschaftsvermittelter krankheiten oder leiden
KR20130041962A (ko) 2010-07-23 2013-04-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 식작용 세포를 사용하여 질환 또는 상태를 검출하는 방법
MX361944B (es) 2010-07-23 2018-12-19 President And Fellows Of Harvard College Star Metodos para detectar firmas de enfermedad o condiciones en fluidos corporales.
CA2806293A1 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
US9751922B2 (en) 2012-04-06 2017-09-05 National Institute Of Advanced Industrial Science And Technology Protein tag, tagged protein, and protein purification method
MX2014015425A (es) 2012-06-15 2015-07-14 Harry Stylli Metodos para detectar enfermedades o condiciones.
EA201590024A1 (ru) 2012-06-15 2015-05-29 Гарри Стилли Способы определения заболеваний или состояний с применением циркулирующих болезненных клеток
EP4202441A3 (de) 2013-03-09 2023-07-26 Immunis.AI, Inc. Genexpressionsprofil in makrophagen zur diagnose von krebs
EP2965086A4 (de) 2013-03-09 2017-02-08 Harry Stylli Verfahren zum nachweis von prostatakrebs
EP4075139B1 (de) 2014-09-11 2024-05-22 Immunis.AI, Inc. Verfahren zum nachweis von prostatakrebs

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008379A1 (en) * 1996-08-27 1998-03-05 Dana-Farber Cancer Institute Methods for identifying modulators of cellular interactions mediated by osteopontin
WO2000063241A2 (en) * 1999-04-15 2000-10-26 Children's Medical Center Corporation Methods and compositions for modulating an immune response
WO2001071358A1 (en) * 2000-03-23 2001-09-27 Glaxo Group Limited Method of screening for inhibitors of osteopontin
WO2001075165A2 (en) * 2000-03-30 2001-10-11 Elan Pharmaceuticals, Inc. Screening markers and methods for neurodegenerative disorders
WO2002081522A1 (fr) * 2001-04-05 2002-10-17 Immuno-Biological Laboratories Co., Ltd. Anticorps dirigé contre l'ostéopontine, et son utilisation
WO2002092122A2 (en) * 2001-05-17 2002-11-21 Applied Research Systems Ars Holding N.V. Use of osteopontin for the treatment and/or prevention of neurologic diseases

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008379A1 (en) * 1996-08-27 1998-03-05 Dana-Farber Cancer Institute Methods for identifying modulators of cellular interactions mediated by osteopontin
WO2000063241A2 (en) * 1999-04-15 2000-10-26 Children's Medical Center Corporation Methods and compositions for modulating an immune response
WO2001071358A1 (en) * 2000-03-23 2001-09-27 Glaxo Group Limited Method of screening for inhibitors of osteopontin
WO2001075165A2 (en) * 2000-03-30 2001-10-11 Elan Pharmaceuticals, Inc. Screening markers and methods for neurodegenerative disorders
WO2002081522A1 (fr) * 2001-04-05 2002-10-17 Immuno-Biological Laboratories Co., Ltd. Anticorps dirigé contre l'ostéopontine, et son utilisation
WO2002092122A2 (en) * 2001-05-17 2002-11-21 Applied Research Systems Ars Holding N.V. Use of osteopontin for the treatment and/or prevention of neurologic diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KIEFER ET AL: "The cDNA and derived amino acid sequence for human osteopontin", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 17, no. 8, 1989, pages 3306, XP002108335, ISSN: 0305-1048 *

Also Published As

Publication number Publication date
DE10291986D2 (de) 2004-04-15
EP1389306A2 (de) 2004-02-18
WO2002090974A2 (de) 2002-11-14
US20070264197A1 (en) 2007-11-15
US20040152138A1 (en) 2004-08-05
US7202044B2 (en) 2007-04-10
AU2002341488A1 (en) 2002-11-18
CA2446666A1 (en) 2002-11-14
JP2004532633A (ja) 2004-10-28

Similar Documents

Publication Publication Date Title
WO2002082075A3 (de) Verfahren zum nachweis chronisch-demenzieller erkrankungen, zugehörige peptide und nachweisreagenzien
WO2002090974A3 (de) Verfahren zum nachweis einer progedienten, chronisch-demenziellen erkrankung, zugehörige peptide und nachweisreagenzien
WO2002059604A8 (en) Diagnosis and treatment of multiple sclerosis
WO2005111233A3 (en) Methods and kits to detect hereditary angioedema type iii
SG134283A1 (en) Biomarkers for liver fibrotic injury
WO2003048775A3 (de) Peptide und verfahren zum nachweis von morbus alzheimer und zur unterscheidung von morbus alzheimer gegenüber anderen demenziellen erkrankungen
WO2003028543A3 (en) Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease
ATE449192T1 (de) Mit dem risiko von obesität und typ-2-diabetes assoziierter haplotyp des gens enpp1 (pc1) und anwendungen davon
WO2003000842A3 (en) Novel proteins and nucleic acids encoding same
EP0753743A3 (de) Vitamin-D-Bestimmung
WO2002004949A3 (en) Reagents and methods for identification of binding agents
WO2006078853A3 (en) Thioredoxin interacting protein (txnip) as regulator of vascular function
WO2002081498A3 (en) Novel proteins and nucleic acids encoding same
WO2003087138A3 (en) Methods for identifying polypeptide factors interacting with rna
WO2000022122A3 (en) Genes, proteins and biallelic markers related to central nervous system disease
WO2003010327A3 (en) Novel proteins and nucleic acids encoding same
WO2001062785A3 (en) Protein and gene and their use for diagnosis and treatment of schizophrenia
WO2003089934A3 (de) Verfahren zur diagnose von entzündungserkrankungen und infektionen mittels bestimmung von lasp-1/lap-1
WO2002057793A3 (en) Method of detecting prp protein and kits therefor
WO2001063294A3 (en) Diagnosis of bipolar affective disorder (bad) and unipolar depression
WO2004082455A3 (en) Method for detecting alzheimer’s disease and corresponding peptides and detection reagents
WO2001069261A3 (en) Proteins, genes and their use for diagnosis and treatment of vascular dementia
WO2001063295A3 (en) Dpi-6, a therapeutic biomarker in neurological disorders
WO2002072757A3 (en) Novel proteins and nucleic acids encoding same
WO1997004099A3 (de) Papillomviren, mittel zu deren nachweis sowie zur therapie von durch sie verursachten erkrankungen

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2446666

Country of ref document: CA

Ref document number: 10476976

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2002588182

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002742729

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002742729

Country of ref document: EP

REF Corresponds to

Ref document number: 10291986

Country of ref document: DE

Date of ref document: 20040415

Kind code of ref document: P

WWE Wipo information: entry into national phase

Ref document number: 10291986

Country of ref document: DE